Role of inflammation and endothelial dysfunction in the pathogenesis of cardiac syndrome

Future Cardiology

Volumn 2, Issue 1, 2006, Pages 63-73

  Gil Ortega, Ignacio ^a   Rivas, Raquel Marzoa ^a   Vázquez, Ramón Ríos ^a   Kaski, Juan Carlos ^a  

^a ST GEORGE'S UNIVERSITY OF LONDON   (United Kingdom)

Author keywords

Angina; Cardiac syndrome X; Chest pain and angiographically normal coronary arteries; Endothelial dysfunction

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; ACETYLCHOLINE; ANGIOTENSIN II; ARGININE; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; C REACTIVE PROTEIN; CALCIUM CHANNEL BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENDOTHELIAL LEUKOCYTE ADHESION MOLECULE 1; ENDOTHELIN 1; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; IMIPRAMINE; INTERCELLULAR ADHESION MOLECULE 1; ISOSORBIDE DINITRATE; LOW DENSITY LIPOPROTEIN CHOLESTEROL; METHACHOLINE; METHYLERGOMETRINE; NITRIC ACID DERIVATIVE; NITRIC OXIDE SYNTHASE; PADGEM PROTEIN; PAPAVERINE; PROSTACYCLIN; VASCULAR CELL ADHESION MOLECULE 1; VASOCONSTRICTOR AGENT;

ANGINA PECTORIS; ANGIOCARDIOGRAPHY; ANTIINFLAMMATORY ACTIVITY; ATHEROSCLEROSIS; CARDIAC SYNDROME X; CLINICAL FEATURE; DISEASE ASSOCIATION; DRUG EFFICACY; ELECTROCARDIOGRAPHY MONITORING; ENDOTHELIAL DYSFUNCTION; ESTROGEN DEFICIENCY; EXERCISE TEST; HEART DISEASE; HEART MUSCLE ISCHEMIA; HEART PROTECTION; HUMAN; INFLAMMATION; MEDICAL DOCUMENTATION; MICROANGIOPATHY; PATHOGENESIS; PATIENT CARE; POSTMENOPAUSE; PREVALENCE; PRIORITY JOURNAL; REVIEW; SYMPTOMATOLOGY; THORAX PAIN;

EID: 33646538115     PISSN: 14796678     EISSN: 17448298     Source Type: Journal    
DOI: 10.2217/14796678.2.1.63     Document Type: Review

References (107)

1. Arbogast R, Bourassa MG: Myocardial function during atrial pacing in patients with angina pectoris and normal coronary arteriograms: comparison with patients having significant coronary artery disease. Am. J. Cardiol. 32(3), 257-263 (1973).
2. Kemp HG: Left ventricular function in patients with anginal syndrome and normal coronary arteriograms. Am. J. Cardiol. 32, 375-376 (1973).
3. Kaski JC, Crea F, Niyoyannopoulos P et al: Transient myocardial ischaemia during daily life in patients with syndrome X. Am. J. Cardiol. 58, 1242-1247 (1986).
4. Kaski JC: Patophysiology and management of patients with chest pain and normal coronary arteriograms (Cardiac Syndrome X). Circulation 109, 568-572 (2004).
5. Kaski JC: Cardiac syndrome X and microvascular angina. In: Kaski JC, ed. Chest pain with normal coronary angiograms: pathogenesis, diagnosis and management. Kluwer Academy Publishers, London, UK. 1-12 (1999).
6. Vázquez-Rey E, Kaski JC: Sindrome X cardiovascular y disfunción endotelial. Rev. Esp. Cardiol. 56(2), 181-192 (2003).
7. Phibbs B, Flemming T, Ewy GA et al: Frequency of normal coronary arteriograms in three academic medical centers and one community hospital. Am. J. Cardiol. 62, 472-474 (1988).
8. Germing A, Lindstaedt M, Ulrich S et al.: Normal angiogram in acute coronary syndrome - preangiographic risk stratification, angiographic findings and follow-up. Int. J. Cardiol. 99(1), 19-23 (2005).
9. Kaski JC: Overview of gender aspects of cardiac syndrome X. Cardiovasc. Res. 53, 620-626 (2002).
10. Rosano GMC, Collins P, Kaski JC et al: Syndrome X in women associated with oestrogen deficiency. Eur. Heart J. 16, 1610-1614 (1995).
11. Buchthal SD, den Hollander JA, Merz CN et al: Abnormal myocardial phosphorus-31 nuclear magnetic resonance spectroscopy in women with chest pain but normal coronary angiograms. N. Engl. Med. 342(12), 829-835 (2000).
12. Kaski JC, Rosano GM, Collins P et al: Cardiac syndrome X: clinical characteristics and left ventricular function. Long-term follow-up study. J. Am Coll. Cardiol. 25, 807-814 (1995).
13. Cox ID, Hann CM, Kaski JC: Low dose imipramine improves chest pain but not quality of life in patients with angina and normal coronary angiograms. Eur. Heart J. 19(2), 250-254 (1998).
14. Atienza F, De Velasco JA: Assessment of quality of life in patients with syndrome X. In: Kaski JC (ed). Chest pain with normal coronary angiograms. Pathogenesis, diagnosis and management. Norwell, MA, USA. 187-194 (1999).
15. Nihoyannopoulos P, Kaski JC, Crake T et al: Absence of myocardial dysfunction during stress in patients with syndrome X. J. Am. Coll. Cardiol. 18 (6), 1463-1470 (1991).
16. Geltman EM, Henes CG, Senneff MJ et al.: Increased myocardial perfusion at rest and diminished perfusion reserve in patients with angina and angiographically normal coronary arteries. J. Am. Coll. Cardiol. 16, 586-595 (1990).
17. Fragasso G, Rosetta E, Dosio, F et al: High prevalence of thallium-201 reserve distribution phenomenon in patients with syndrome X. Eur. Heart J. 17, 1482-1487 (1996).
18. Satake O, Kajinami K, Ishikawa Y et al: Myocardial glucose metabolism assessed by positron emission tomography and the histopatologic findings of microvessels in syndrome X. Circ. J. 68, 220-226 (2004).
19. Candia ED, Lanza GA, Romagnoli E et al: Abnormal pH-sensing of platelet Na/H exchanger in patients with cardiac syndrome X. Intern. J. Cardiol. 100, 371-376 (2005).
20. Maseri A, Crea F, Kaski JC et al.: Mechanisms of angina pectoris in syndrome X. J. Am. Coll. Cardiol. 17, 499-506 (1991).
21. Cannon RO, Bonow RO, Bacharach SL et al: Left ventricular dysfunction in patients with angina pectoris, normal epicardial coronary arteries, and abnormal vasodilator reserve. Circulation 71, 218-226 (1985).
22. Panting JR, Gatehouse PD, Yang GZ et al: Abnormal subendocardial perfusion in cardiac syndrome X detected by cardiovascular magnetic resonance imaging. N. Engl. J. Med. 346, 1948-1953 (2002).
23. Verma S, Anderson TJ: Fundamentals of endothelial function for the clinical cardiologist. Circulation 105, 546-549 (2002).
24. Verma S, Buchanan M, Anderson TJ: Endothelial function testing as a biomarker of vascular disease. Circulation 108, 2054-2059 (2003).
25. Lüscher TF, Barton M: Biology of endothelium. Clin. Cardiol. 20(Suppl. II), II3-II10 (1997).
26. Lüscher TF, Richard VV, Tschudi M et al: Endothelial control of vascular tone in large and small coronary arteries. J. Am. Coll. Cardiol. 15, 519-527 (1990).
27. Furchgott RF, Zawadski JV: The obligatory role of endothelial cells in the relaxation of arterial smooth muscle by acetycholine. Nature 288, 373-376 (1980).
28. Quyyuumi AA, Darak N, Andrews NP et al: Contribution to nitric oxide to metabolic coronary vasodilation in the human heart. Circulation 92, 320-326 (1995).
29. Rubanyi GM: Maintenance of 'basal' vascular tone may represent a physiological role for endothelin. J. Vasc. Med. Biol. 1, 315-316 (1989).
30. Corretti MC, Anderson TJ, Benjamin EJ et al.: Guidelines for the ultrasound assessment of endothelial-dependent flow-mediated vasodilation of brachial artery. J. Am. Coll. Cardiol. 39, 257-265 (2002).
31. Davignon J, Ganz P: Role of endothelial dysfunction in atherosclerosis. Circulation 109(Suppl. III), III27-III32 (2004).
32. Yanagisawa M, Kurihana H, Kimura S et al: A novel potent vasoconstrictor peptide produced by vascular endothelial cells. Nature 332, 411-4115 (1988).
33. Masaka T: The discovery of endothelins. Cardiovasc. Res. 39, 530-533 (1998).
34. Levin ER: Mechanisms of disease: endothelins. N. Engl. J. Med. 333, 353-363 (1995).
35. Bogaty P, Hackett D, Davies G et al.: Endothelium in human congestive heart failure. Circulation 89, 1580-1586 (1994).
36. Sowers JR: Hypertension, angiotensin II and oxidative stress. N. Engl. J. Med. 346, 1999-2001 (2002).
37. Kinlay S, Behrendt D, Wainstain M et al.: The role of endothelin-1 in the constriction of human atherosclerotic coronary arteries. Circulation 104, 1114-1118 (2001).
38. Kaski JC, Cox ID, Crook JR et al.: Differential plasma endothelin levels in subgroups of patients with angina and angiographically normal coronary arteries. Am. Heart J. 136, 412-417 (1998).
39. Kaski JC, Elliott PM, Salomone O et al.: Concentration of circulating plasma endothelin in patients with angina and normal coronary angiograms. Br. Heart J. 74(6), 620-624 (1995).
40. Stewart DJ, Cernacek P, Costello KB et al: Elevated endothelin-1 in heart failure and loss of normal response to posture change. Circulation 85, 510-517 (1992).
41. Vita JA, Treasure CB, Nabel EG et al.: Coronary vasomotor response to acetylcholine relates to risk factors for coronary artery disease. Circulation 81, 491-497 (1990).
42. Schächinger V, Britten MB, Elsner M et al: A positive family history of premature coronary artery disease is associated with impaired endothelium-dependent coronary blood flow regulation. Circulation 100, 1502-1508 (1999).
43. Glasser SP, Selwyin AP, Ganz P: Atherosclerosis: risk factors and the vascular endothelium. Am. Heart J. 131, 379-384 (1996).
44. Celermajer DS, Sorensen KE, Georgakopoulos D et al.: Cigarette smoking is associated with dose-related and potentially impairment of endothelium-dependent dilation in healthy young adults. Circulation 88(Part I), 2149-2155 (1993).
45. Ghiadoni L, Donald AE, Cropley M et al.: Mental stress induces transient endothelial dysfunction in humans. Circulation 102, 2473-2478 (2000).
46. Egashira K, Inou T, Hirooka Y et al.: Effects of age on endothelium-dependent vasodilation of resistance coronary artery by acetylcholine in humans. Circulation 88, 77-81 (1993).
47. Ludmer PL, Selwyn AP, Shook TL et al.: Paradoxical vasoconstriction induced by acetylcholine in atherosclerotic coronary arteries. N. Engl. J. Med. 315, 1046-1051 (1986).
48. Turhan H, Saydam GS, Erbay AR et al: Increased plasma soluble adhesion molecules; ICAM-1, VCAM-1, and E-selectin levels in patients with slow coronary flow. Int. J. Cardiol. In Press. doi: 10.1016/ j.ijcard.2005.05.008
49. Beltrame JF, Limaye SB, Horowitz JD: The coronary slow flow phenomenon: a new coronary microvascular disorder. Cardiology 97(4), 197-202 (2002).
50. Aguilar-Salinas CA, Rojas R, Gómez-Pérez FJ: Analysis of the agreement between the World Health Organization criteria and the National Cholesterol Education Program III definition of metabolic syndrome: results from a population-based survey. Diabetes Care 26(5), 1635 (2003).
51. Piatti PM, Fragasso G, Monti LD et al.: Endothelial and metabolic characteristics of patients with angina and angiographically normal coronary arteries. J. Am. Coll. Cardiol. 34, 1452-1460 (1999).
52. Piatti PM, Monti LD, Conti M et al.: Hypertrigliceridemia and hyperinsulinemia are potent inducers of endothelin-1 release in humans. Diabetes 45, 316-321 (1996).
53. Cox ID. Kaski JC: Endothelin: an important mediator in the pathophysiology of syndrome X? In: Kaski JC (Ed). Chest pain with normal coronary angiograms. Pathogenesis, diagnosis and management. Norwell, MA, USA. 101-114 (1999).
54. Arcaro G, Cretti A, Balzano S et al.: Insulin causes endothelial dysfunction in humans: sites and mechanisms. Circulation 105, 576-582 (2002).
55. Lundman P, Eriksson MJ, Stuhlinger M et al: Mild-to-moderate hypertriglyceridemia in young men is associated with endothelial dysfunction and increased plasma concentrations of asymmetric dimethylarginine. J. Am. Coll. Cardiol. 38, 111-116 (2001).
56. Al Suwaidi J, Higano ST, Holmes DR Jr et al.: Obesity is independently associated with coronary endothelial dysfunction in patients with normal or mildly diseased coronary arteries. J. Am. Coll. Cardiol. 37, 1523-1528 (2001).
57. Bøtker HE. Møller N, Schmitz O et al.: Myocardial insulin resistance in patients with syndrome X. J. Clin. Invest. 100, 1919-1927 (1997).
58. Palloshi A, Fragasso G, Piatti P et al.: Effect of oral L-arginine on blood pressure and symptoms and endothelial function in patients with systemic hypertension, positive exercise tests and normal coronary arteries. Am. J. Cardiol. 93, 930-935 (2004).
59. Masci PG, Laclaustra M, Garcia Lara J et al.: Brachial artery flow-mediated dilation and myocardial perfusion in patients with cardiac syndrome X. Am. J. Cardiol. 95, 1478-1480 (2005).
60. Zeiher AM, Drexler H, Wollschlaeger H et al: Endothelial dysfunction of the coronary microvasculature is associated with impaired coronary blood flow regulation in patients with early atherosclerosis. Circulation 84, 1984-1992 (1991).
61. Darling RC, Raines JK, Brener BJ et al: Segmental volume plethysmography in the diagnosis of lower extremity arterial occlusive disease. J. Cardiovasc. Surg. 23(2), 125-129 (1982).
62. Tousoulis D, Davies GJ, Asimakopoulos G et al.: Vascular cell adhesion molecule-1 and intercellular adhesion molecule-1 serum level in patients with chest pain and normal coronary arteries (syndrome X). Clin. Cardiol. 24, 301-304 (2001).
63. Egashira K, Inou T, Hirooka Y et al: Evidence of impaired endothelium-dependent coronary vasodilatation in patients with angina pectoris and normal coronary angiograms. N. Engl. J. Med. 328, 1659-1664 (1993).
64. Egashira K, Hirooka Y, Kuga T et al: Effect of L-arginine supplementation on endothelium-dependent coronary vasodilation in patients with angina pectoris and normal coronary arteriograms. Circulation 94, 130-134 (1996).
65. Chauhan A, Mullins PA, Taylor M et al.: Both endothelium-dependent and endothelium-independent function is impaired in patients with angina pectoris and normal angiograms. Eur. Heart J. 18, 60-68 (1997).
66. Hansson GK: Inflammation, atherosclerosis and coronary artery disease. Mechanisms of disease. N. Engl. J. Med. 352, 1685-1695 (2005).
67. Fitchtischerer S, Rosenberger G, Walter DH et al.: Elevated C-reactive protein levels and impaired endothelial vasoreactivity with coronary artery disease. Circulation 102, 1000-1006 (2000).
68. Gonzalez MA, Selwyn AP: Endothelial function, inflammation and prognosis in cardiovascular disease. Am. J. Med. 115(8A), 99S-106S (2003).
69. Arroyo-Espliguero R, Mollichelli, Avanzas P et al.: Chronic inflammation and increased arterial stiffness in patients with cardiac syndrome X. Eur. Heart J. 24, 2006-2011 (2003).
70. Cosin-Sales J, Pizzi C, Brown S, Kaski JC: C-reactive protein, clinical presentation and ischaemic activity in patients with chest pain and normal coronary angiograms. J. Am. Coll. Cardiol. 41, 1468-1474 (2003).
71. Tomai F: C reactive protein and microvascular function. Heart 90, 727-728 (2004).
72. Teragawa H, Fukuda Y, Matsuda K: Relation between C reactive protein concentrations and coronary microvascular endotelial function. Heart 90, 750-754 (2004).
73. Zouridakis E, Avanzas P, Arroyo-Espliguero R et al.: Markers of inflammation and rapid coronary artery disease progression in patients with stable angina pectoris. Circulation 110, 1747-1753 (2004).
74. Lanza GA, Sestito A, Cammarota G et al: Assessment of systemic inflammation and infective pathogen burden in patients with cardiac syndrome X. Am. J. Cardiol. 94, 40-44 (2004).
75. Lin CP, Lin WT, Leu HB: Differential mononuclear cell activity and endothelial inflammation in coronary artery disease and cardiac syndrome X. Int. J. Cardiol. 89, 53-62 (2003)
76. Hingorani AD, Cross J, Kharbanda RK et al.: Acute systemic inflammation impairs endothelium-dependent dilatation in humans. Circulation 102, 994-999 (2000)
77. Senen K, Ileri M, Alper A et al.: Increased levels of soluble adhesion molecules E-selectin and P-selectin in patients with cardiac syndrome X. Angiology 56, 273-277 (2005).
78. Bugiardini R, Merz CNB: Angina with 'normal' coronary arteries. A changing philosophy. JAMA 293(4), 477-484 (2005).
79. von Mering G, Arant CB, Wessel TR et al.: Abnormal coronary vasomotion as a prognostic indicator of cardiovascular events in women. Results from the National Heart, Lung, and Blood Institute-sponsored Women's Ischaemia Syndrome Evaluation (WISE). Circulation 109, 722-725 (2004)
80. Hochman JS, Tamis JE, Thompson TD et al.: Global Use of Strategies in Acute Coronary Syndromes IIb Investigators. Sex, clinical presentation, and outcome in patients with acute coronary syndromes. N. Engl. J. Med. 341, 226-232 (1999).
81. Halcox JPJ, Schenke WH, Zalos G et al: Prognostic value of coronary vascular endothetial dysfunction. Circulation 106, 653-658 (2002)
82. Bugiardini R, Manfrini O, Pizzi C et al: Endothelial function predicts future development of coronary artery disease. A study of women with chest pain and normal coronary angiograms. Circulation 109, 2518-2523 (2004)
83. Suwaidi JA, Hamasaki S, Higano, ST et al: Long-term follow-up of patients with mild coronary artery disease and endothelial dysfunction. Circulation 101, 948-954 (2000).
84. Lerman A: Restenosis. Another 'dysfunction' of endothelium. Circulation 111, 8-10 (2005).
85. Lerman A, Zeiher AM: Endothelial function. Cardiac events. Circulation 111, 363-368 (2005).
86. Widlansky ME, Gokce N, Keaney JF et al: The clinical implications of endothelial dysfunction. J. Am. Cardiol. 42, 1149-1160 (2003).
87. Quyyumi AA: Prognostic value of endothelial function. Am. J. Cardiol. 91(Suppl.), 19H-24H (2003).
88. Landmesser U, Hornig B, Drexler H: Endothelial function: a critical determinant in atherosclerosis? Circulation 109(Suppl. II), II27-II33 (2004).
89. Schachinger V, Britten MB, Zeiher et al.: Prognostic impact of coronary vasodilator dysfunction on adverse long-term outcome of coronary heart disease. Circulation 101, 1899-1906 (2000).
90. Cox ID, Clague JR, Bagger JP, Ward DE, Kaski JC: Endothelial dysfunction, subangiographic atheroma, and unstable symptoms in patients with chest pain and normal coronary arteriograms. Clin. Cardiol. 23(9), 645-652 (2000).
91. Wiedermann O, Schwartz A, Apfelbaum M: Anatomic and physiologic heterogeneity in patients with syndrome X. J. Am. Coll. 25, 1310-1317 (1995).
92. Kaski JC, Valenzuela LF: Therapeutic options for the management of patients with CSX. Eur. Heart J. 22, 283-293 (2001).
93. Kaski JC, Aldama G, Cosin-Sales J: Cardiac Syndrome X: diagnosis, pathogenesis and management. Am. J. Cardiovasc. Drugs 4(3), 179-194 (2004).
94. Braunwald E, Antman E, Beasley J et al: ACC/AHA 2002 guideline update for the management of patients with instable angina and non-ST segment elevation myocardial infarction - summary article: a report of the American Collage of Cardiology/American Heart Association task force on practice guidelines (committee of the management of patients with unstable angina). J Am. Coll. Cardiol. 40(7), 1366-1374 (2002).
95. Laufs U, La Fata V, Plutzky J et al: Upregulation of endothelial nitric oxide synthase by HMG CoA reductase inhibitors. Circulation 97, 1129-1135 (1998).
96. Rosenson RS: Statin therapy: new therapy for cardiac microvascular dysfunction. Eur. Heart J. 24, 1993-1994 (2003).
97. Egashira K, Hirooka Y, Kai H et al: Reduction in serum cholesterol with pravastatin improves endothelium-dependent coronary vasomotion in patients with hypercholesterolemia. Circulation 89, 2519-2524 (1994).
98. Treasure CH, Klein L, Weintraub WS et al: Beneficial effects of cholesterol-lowering therapy on the coronary endothelium in patients with coronary artery disease. N. Engl. J. Med. 332, 481-487 (1995).
99. Fáblán E, Varga A, Picano E et al: Effect of simvastatin on endothelial function in cardiac syndrome X patients. Am. J. Cardiol. 94, 652-665 (2004).
100. Kayikcioglu M, Payzin S, Yavuzgil O et al: Benefits of statin treatment in cardiac syndrome X. Eur. Heart J. 24, 1995-2005 (2003).
101. Kaski JC, Rosano G, Gavrielides S et al: Effects of angiotensin-converting enzyme inhibition on exercise-induced angina and ST depression in patients with microvascular angina. J. Am. Coll. Cardiol. 23, 652-657 (1994).
102. Chen JW, Hsu NW, Wu TC et al.: Longterm angiotensin-converting enzyme inhibition reduces plasma asymetric dimethylarginine and improves endothelial nitric oxide bioavailability and coronary microvascular function in patients with syndrome X. Am. J. Cardiol. 90, 974-982 (2002).
103. Fujiwara T, Horikoshi H: Troglitazone and related compounds. Therapeutic potential beyond diabetes. Life Sciences 67, 2405-2416 (2000).
104. Dandona P, Aljada A: Endothelial dysfunction in patients with Type 2 diabetes and the effects of thiazolldinedione antidiabetic agents. J. Diabetes Comp. 18, 91-102 (2004).
105. Haffner SM, Greenberg AS, Weston WM et al: Effect of rosiglitazone treatment on non-traditional markers of cardiovascular disease in patients with type-2 diabetes mellitus. Circulation 106, 679-684 (2002).
106. Garg R, Kumbkarni Y, Aljada A et al.: Troglazitones reduces reactive oxygen species generation by leukocytes and lipid peroxidation and improves flow-mediated vasodilation in obese subjects. Hypertension 36, 430-435 (2000).
107. Bøtker HE, Møller N, Schmitz O et al: Myocardial insulin resistance in patients with syndrome X. J. Clin. Invest. 100, 1919-1927 (1997).